Search Results (112)

Assessing motor symptoms in Parkinson’s disease (PD) is challenging due to the progressive evolution of the condition and the variability of symptoms, which are not fully captured by periodic clinical visits. In this context, wearable sensors and machine learning (ML) have emerged as a viable path toward objective and continuous monitoring, although achieving robust generalization to free-living conditions remains a challenge. This work explores the egg-beating task, a simple everyday activity, as a digital approach for PD motor assessment using smartwatch-based inertial measurements and ML techniques. Twenty-two individuals with PD and sixteen healthy controls (HC) completed a one-minute egg-beating task while wearing a smartwatch equipped with tri-axial accelerometer and gyroscope sensors. Data were recorded both under supervised clinical conditions and during unsupervised home sessions. Time- and frequency-domain features were extracted from the inertial signals, and models trained exclusively on supervised recordings were then tested on supervised, unsupervised, and combined data. PD participants showed systematically lower movement amplitude, slower oscillation frequency, and a progressive drop in signal energy over the course of the task, all of which align with the characteristic features of bradykinesia. The support vector machine achieved the best overall performance, reaching 90% accuracy in distinguishing PD from healthy controls under supervised conditions, with a reduction of less than 4% when applied to unsupervised data. These results support the egg-beating task as a practical and ecologically valid method for real-world motor assessment, with potential for future use in remote monitoring and longitudinal assessment. Full article

Background: Dural venous sinus thrombosis (DVST) is an uncommon but potentially life-threatening cerebrovascular disorder requiring early diagnosis to prevent serious complications. Although CE-MRV is the reference standard, routine brain MRI is often the first imaging study in patients with nonspecific neurological symptoms, and the sinus-specific diagnostic performance of individual sequences remains incompletely defined. Purpose: To evaluate the diagnostic performance and inter-reader agreement of routine brain MRI sequences for DVST detection using a sinus-specific framework. Methods: This retrospective case–control study included 140 patients (34 with DVST, 106 age-matched controls) imaged on 1.5 T and 3.0 T scanners. Two blinded neuroradiologists evaluated six unenhanced sequences (sagittal/axial T1WI, T2WI, FLAIR, DWI [b = 1000 s/mm²], and SWI) across four dural sinuses, using CE-MRV and CE-3D T1WI as the reference standards. Logistic regression and Cohen’s κ assessed diagnostic performance and inter-reader agreement, respectively. Results: Globally, DWI with FLAIR achieved 97.9% accuracy, 91.2% sensitivity, and 100% specificity (AUC = 0.997). Optimal sequences varied by sinus: sagittal T1WI with SWI for the superior sagittal sinus (accuracy = 99.3%), DWI with SWI for the transverse sinus (97.9%), DWI with FLAIR and T2WI for the sigmoid sinus (98.6%), and SWI with axial T1 for the straight sinus (100%). Inter-reader agreement was substantial to almost perfect for routine sequences (mean κ = 0.874) and almost perfect for CE-MRV and CE-3D T1WI (κ = 0.98). Conclusions: Routine brain MRI provides reliable DVST detection with a sinus-tailored multisequence strategy. DWI and FLAIR offer robust diagnostic performance in global evaluation, while T1WI, SWI and T2WI add segment-specific value, reserving CE-MRV and CE-3D T1WI for equivocal or clinically suspicious cases. Full article

Background: Fatigue is a common and disabling symptom in axial spondyloarthritis (axSpA), yet its magnitude relative to the general population and potential sex-specific differences remain insufficiently characterized, particularly in older adults. We therefore aimed to assess fatigue in adults aged ≥ 50 years with axSpA, using the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F) scale, to compare fatigue levels with age- and sex-matched controls, and to explore sex-specific differences and clinical factors associated with fatigue. Methods: We conducted an observational case–control study including consecutive patients with axSpA aged ≥ 50 years and control subjects frequency-matched by age and sex. Fatigue was assessed using the FACIT-F, and clinically relevant fatigue was defined as a FACIT-F score < 40. Case–control comparisons were stratified by sex, and sex-stratified multivariable linear regression models were applied. Results: The study included 173 patients with axSpA (120 men, 53 women; mean age: 64.2 years) and 383 controls. Clinically relevant fatigue was more frequent in women than in men (84.9% vs. 50.0%; p < 0.001). Women reported more severe fatigue than men (FACIT-F: 29.4 ± 10.4 vs. 37.4 ± 10.2; p < 0.001). In case–control comparisons, fatigue was greater in patients than in controls in both sexes, with descriptively larger differences among women. In sex-stratified multivariable analyses, the ASAS Health Index (ASAS-HI) was independently associated with fatigue in both men and women. In reduced models including age, BASDAI, and ASAS-HI, ASAS-HI remained independently associated with FACIT-F in both men (β: −1.74, 95% CI: −2.08 to −1.41) and women (β: −1.80, 95% CI: −2.35 to −1.26; p < 0.001 for both). BASDAI showed an additional independent association in women (β: −1.19, 95%: CI −2.09 to −0.30; p = 0.010), but not in men. Conclusions: Fatigue is highly prevalent and clinically relevant in adults aged ≥50 years with axSpA, with a clear sex-specific pattern. Women experience a greater fatigue burden, and comparisons with controls suggest a larger excess among women. Fatigue represents an important dimension of disease burden in axSpA, with stronger associations with overall health status than with conventional inflammatory measures. Full article

Background/Objectives: Continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) improves motor fluctuations in advanced Parkinson’s disease (PD), but some patients continue to experience residual motor and non-motor fluctuations despite optimized infusion parameters. We describe two patients receiving CSFLI in whom the addition or reintroduction of opicapone was associated with improvement in persistent fluctuations. In one patient, clinical findings were further explored using wearable sensor monitoring. Methods: Two patients with advanced PD treated with CSFLI and residual fluctuations received add-on opicapone. Clinical evaluation included neurological examination, assessment of motor fluctuations, and documentation of antiparkinsonian therapy before and after opicapone introduction. In one patient, motor performance was additionally evaluated with wearable sensor monitoring during the Timed Up and Go test and the 6-minute walk test before (T0) and three months after opicapone introduction (T1). Results: In both cases, opicapone 50 mg once daily was associated with rapid improvement in residual motor and non-motor fluctuations during CSFLI therapy. In the first patient, freezing episodes and unpredictable akinesia resolved. In the second patient, the reintroduction of opicapone improved morning slowness, axial symptoms, and dorsal pain. Wearable sensor analysis showed increased walking distance during the 6-minute walk test, higher walking speed, reduced Timed Up and Go duration, increased step length, and reduced step length variability. Conclusions: These preliminary observations suggest that opicapone may deserve further investigation as a potential adjunctive strategy in selected patients receiving CSFLI who continue to experience residual fluctuations despite optimized infusion therapy. Wearable sensor monitoring may provide objective support for treatment assessment in this setting. Full article

Background/Objectives: Cauda equina syndrome (CES) is a rare but severe complication of lumbar disc herniation (LDH). This study aimed to assess the diagnostic value of the dural sac cross-sectional area (DSCSA) in predicting CES in affected patients. Methods: In this retrospective observational study, we analyzed 99 patients who underwent surgery for LDH, including cases with CES, between 2014 and 2023. The DSCSA was measured at the narrowest level of the dural sac using axial T2-weighted magnetic resonance imaging. Univariable and multivariable logistic regression were performed on DSCSA and other candidate risk factors. Results: Among the patients with LDH, nine (9.1%) had CES. In multivariable logistic regression, DSCSA was associated with CES, with an adjusted odds ratio of 0.79 (95% confidence interval [CI]: 0.62–0.90, p = 0.011). Exploratory receiver operating characteristic analysis identified an optimal DSCSA cut-off of 31.16 mm², yielding 100% sensitivity, 92.2% specificity, and an area under the curve of 0.974 (95% CI: 0.944–1.000, p < 0.001). Conclusions: Smaller DSCSA was associated with CES in patients with LDH. Patients with a DSCSA of approximately 30 mm² or less may require closer monitoring for the development of CES symptoms. Given the limited number of CES cases, these findings should be interpreted cautiously and validated in larger studies. Full article

Chronic chikungunya disease (CCD) affects approximately 30–50% of infected individuals and is associated with persistent inflammatory arthritis, chronic pain, and long-term functional disability. We conducted a prospective observational cohort study including 584 patients with laboratory-confirmed chikungunya infection, evaluated between 3 and 12 months after acute infection, to better understand the natural history, risk factors, clinical presentation, and treatment patterns of CCD. Here, we present a cross-sectional analysis derived from this cohort. Older age, female sex, and higher body mass index were identified as major risk factors for CCD. Four distinct clinical phenotypes were identified: Axial (12.2%), defined by inflammatory axial pain regardless of peripheral manifestations; Oligoarthritis (18.1%), defined by fewer than four swollen joints; Polyarthritis (10.6%), defined by four or more swollen joints; and Pain without Swelling (70.4%), characterized by myalgia and/or arthralgia in the absence of objective inflammatory findings on physical examination. The axial phenotype could overlap with peripheral phenotypes, whereas oligoarthritis, polyarthritis, and pain without swelling were mutually exclusive categories. These phenotypes differed substantially in symptom burden and clinical impact. Patients with the Pain without Swelling phenotype had longer symptom duration, whereas Axial and Polyarthritis phenotypes were associated with greater functional impairment and higher disease burden. These findings reinforce the clinical heterogeneity of CCD and support the potential value of phenotype-based approaches for clinical management and future therapeutic research. Full article

(1) Background: The characteristics of rare diseases (RDs) vary considerably—not only between different disease types but also between individual patients with the same condition. In the Roma community, we analyzed the most frequent rare genetic disorders related to the founder effect. (2) Methods: This retrospective study, conducted between January 2019 and January 2025 at the Clinical Genetics and Metabolics Outpatient Clinic in Košice, included 61 patients aged from infancy to 25 years diagnosed with hypomyelinating leukodystrophy 14, pontocerebellar hypoplasia type 1B, neuronal ceroid lipofuscinosis 7, or TMEM70 deficiency. (3) Results: This study includes the largest known cohort of patients with hypomyelinating leukodystrophy 14 caused by the UFM1 c.-273_-271delTCA mutation, predominantly affecting males (n = 17). The disorder is severe, with most patients dying before one year of age, and is characterized by inspiratory stridor, axial hypotonia, spastic quadriparesis, pseudobulbar signs, and microcephaly. In a separate group with pontocerebellar hypoplasia type 1B, six Roma patients (three males, three females) shared the same EXOSC3 mutation. Diagnosis occurred at an average age of 8.8 months, and most children did not survive beyond three years. Common features included microcephaly, severe hypotonia, and spastic quadriplegia. Thirteen children from eight families were diagnosed with neuronal ceroid lipofuscinosis 7, all carrying the same MFSD8 mutation. Symptoms typically began with psychomotor regression between ages 3 and 4, along with intellectual disability and seizures, which were more frequent in males. The mean age at diagnosis was 4.5 years, and eight children died before age nine. Finally, 25 patients with TMEM70 deficiency associated with Roma ancestry were identified, predominantly females, with a mean age of 9.95 years and the oldest patient aged 25. Four children died due to severe metabolic crises. Common findings included intellectual disability, global hypotonia, hypertrophic cardiomyopathy, epilepsy, and failure to thrive. (4) Conclusions: Most rare diseases are genetic and carry high morbidity and mortality, with no targeted therapies currently available. Their increased prevalence in the Roma population reflects founder effects and high consanguinity. Prenatal and newborn screening, along with voluntary carrier testing for couples, is essential for proactive health management. Full article

Objective: To investigate the relationship between cardiovascular risk factors and the progression of motor and non-motor symptoms in Parkinson’s disease (PD). Methods: We used data from the Parkinson’s Progression Markers Initiative (PPMI) cohort with a follow-up duration of >5 years. Baseline assessments included genetic analysis, brain MRI, cardiovascular risk factors, and overall cardiovascular disease (CVD) risk. Motor symptoms and non-motor symptoms of PD were evaluated using the Movement Disorders Society revised Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and sub-scores, Hoehn–Yahr stage, and Montreal Cognitive Assessment (MoCA). Statistical analyses comprised univariate and multivariate linear regression and stratified analysis. Results: A total of 169 newly diagnosed PD patients and 78 healthy controls (HCs) were included. At baseline, no significant differences in cardiovascular risk factors or overall CVD risk were observed between PD patients and HCs. Hypertension (β = 6.748, p = 0.040) and hyperlipidemia (β = 8.316, p = 0.005) were associated with faster motor progression. ApoE genotype was correlated with motor progression (β = 7.593, p = 0.007). PD patients with a moderate-to-low CVD risk (<20%) had milder axial motor symptoms (3.0 [IQR, 4.0] vs. 4.0 [IQR, 5.0], p = 0.048) and lower MDS-UPDRS Part I total scores (7.0 [IQR, 6.25] vs. 9.0 [IQR, 7.0], p = 0.039) at last follow-up compared to high-CVD-risk (≥20%) patients. Overall CVD risk was negatively correlated with total MoCA score at last follow-up (β = −0.208, p< 0.001). Conclusions: Cardiovascular risk factors accelerate the progression of motor and non-motor symptoms in PD, suggesting that management of modifiable CVD risk factors may represent a promising target to delay the progression of PD. Full article

Background/Objectives: Spondylarthritis (SA) is characterized by high clinical heterogeneity, often resulting in a discrepancy between systemic inflammation and patient-reported symptoms. While hematologic indices are emerging as cost-effective biomarkers, their role in phenotypic differentiation remains unclear. We investigated the utility of traditional inflammatory markers, including the novel fibrinogen-to-platelet ratio (FPR), in differentiating SA subtypes and predicting patient-reported disease activity. Methods: This cross-sectional study included 64 patients with spondylarthritis: axial SA (n = 32), peripheral SA (n = 8), and psoriatic SA (n = 24). Clinical assessments included the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Functional Index (BASFI). Systemic inflammation was evaluated via C-reactive protein (CRP), fibrinogen, and calculated ratios (NLR, PLR, MLR, and FPR). Principal Component Analysis (PCA) was employed to map the inflammatory architecture, while Receiver Operating Characteristic (ROC) curves evaluated the predictive power for high disease activity (BASDAI ≥ 4). Results: Significant phenotypic differences were observed with the FPR demonstrating superior discriminative capacity (p = 0.003). Patients with peripheral SA exhibited significantly higher FPR (median 1.88) compared to axial (1.33) and psoriatic (1.32) subtypes, and the dedicated ROC analysis for phenotypic discrimination yielded an AUC of 0.866 (95% CI: 0.745–0.987) (1.36, p = 0.039). HLA-B27 prevalence was low overall (31.3%) and in psoriatic SA (4.2%, p = 0.012). Correlation analysis revealed strong associations between BASDAI and BASFI (ρ = 0.79), NLR and MLR (ρ = 0.78), and CRP and fibrinogen (ρ = 0.66). PCA identified two independent inflammatory dimensions explaining 74.8% of variance: neutrophil-hypercoagulable axis (41.4%, driven by NLR, PLR, and MLR), and an acute-phase/fibrinogen axis (33.4%, driven by CRP, fibrinogen, and FPR). Notably, FPR clustered with acute-phase reactants rather than leukocyte-derived ratios, supporting its role as a marker of systemic inflammatory burden. Although fibrinogen is involved in the coagulation cascade, the absence of direct coagulation markers precludes definitive characterization of this component as hypercoagulable. ROC analysis revealed that fibrinogen showed the highest discriminative ability for disease activity (BASDAI ≥ 4), with an AUC of 0.690 (95% CI: 0.519–0.861), followed by NLR (0.621), MLR (0.592), and FPR (0.583). However, overall discriminative performance remained modest, with most 95% confidence intervals crossing 0.5. Conclusions: FPR emerges as a robust phenotypic biomarker capable of discriminating against SA subtypes, particularly identifying peripheral SA with high accuracy and excellent negative predictive value. In contrast, its ability to predict patient-reported disease activity remains limited, reinforcing the distinction between trait and state biomarkers. Exploratory PCA revealed that FPR clusters with acute-phase reactants rather than leukocyte-derived ratios, supporting its biological link to systemic inflammatory burden. These findings advocate for a dual-purpose biomarker approach in SA: FPR for phenotypic stratification and fibrinogen for activity assessment, while clinical indices remain indispensable for symptom monitoring. Validation in larger, prospective cohorts is warranted. Full article

The relationship between lifestyle, ocular biomechanical behavior, and myopia is not well established in the literature. The present study aims to describe changes in ocular biomechanics during adolescence and to explore their relationship with lifestyle factors and myopic progression. Prospective cohort study including 63 adolescents (126 eyes) with a mean age of 14.1 ± 2.6 years old examined twice over a 30 ± 0.9-month period. The data from biomechanics, biometry, corneal tomography, and lifestyle was addressed. The relationships between biomechanical changes, biometric and refractive variation, and lifestyle variables were analyzed using parametric and non-parametric statistics with a significance level of p < 0.05. A biomechanical stiffening trend was found. Axial elongation was 0.12 ± 0.17 mm, and refractive shift was −0.32 ± 0.87 D. The history of allergies was associated with greater axial growth (p = 0.032) and smaller increase in stress–strain-index (SSI) (p = 0.01). Myopization was higher in eyes with ocular surface symptoms (p = 0.049) and those with reported eye-rubbing habits (p = 0.04), with a lower gain in stiffness (p < 0.05). Outdoor activities were associated with higher gain in corneo-scleral stiffness (p < 0.05). Reduced myopization correlated directly with the increase in the SSI (p < 0.05) and inversely with the Integrated Radius (p < 0.05). Greater increases in axial length (AL), vitreous cavity length (VCL), and the ratio between VCL and AL (R_VCL/AL) correlated negatively with the increase in the SSI (p < 0.05). The increase in the R_VCL/AL correlated positively with the time spent on digital devices and negatively with the amount of outdoor activity (p < 0.05). Biomechanics may represent the physiological bridge between the environmental exposure and myopization, as lower gain in corneo-scleral stiffness was consistently associated with greater axial elongation and refractive myopization, with outdoor activity appearing to be protective. Full article

Axial postural abnormalities in Parkinson’s Disease (PD) are traditionally assessed using clinical rating scales, although picture-based assessment is considered the gold standard. This study evaluates the reliability and clinical relevance of two markerless body-tracking frameworks, the RGB-D-based Microsoft Azure Kinect (providing the reference KIN_3D model) and the RGB-only Google MediaPipe Pose (MP), using a synchronous dual-camera setup. Forty PD patients performed a 60 s static standing task. We compared KIN_3D with three MP models (at different complexity levels) across horizontal, vertical, sagittal, and 3D joint angles. Results show that lower-complexity MP models achieved high congruence with KIN_3D for trunk and shoulder alignment (ρ > 0.75), while the lateral view significantly improved tracking of sagittal angles (ρ ≥ 0.72). Conversely, the high-complexity model introduced significant skeletal distortions. Clinically, several angular parameters emerged as robust metrics for postural assessment and global motor impairments, while sagittal angles correlated with motor complications. Unexpectedly, a more upright frontal alignment was associated with greater freezing of gait severity, suggesting that static postural metrics may serve as proxies for dynamic gait performance. In addition, both RGB-only and RGB-D frameworks effectively discriminated between postural severity clusters. While the higher-complexity MP model should be avoided due to inaccurate 3D reconstructions, our findings demonstrate that low- and medium-complexity MP models represent a reliable alternative to RGB-D sensors for objective postural assessment in PD, facilitating the widespread application of objective posture measurements in clinical contexts. Full article

Background/Objectives: Axial spondyloarthritis (axSpA) is a chronic systemic inflammatory disease that adversely affects both physical and mental health. This cross-sectional study aimed to examine the associations between spondyloarthritis features (SpA-fs) and disease-related variables (DRVs: disease duration, Visual Analogue Scale, Ankylosing Spondylitis Disease Activity Score [ASDAS], Bath Ankylosing Spondylitis Disease/Functional Activity Index), as well as potential correlations with quality of life (QoL) and symptoms of anxiety and depression in women with non-radiographic axSpA (nr-axSpA). Methods: This study included 78 women with nr-axSpA. Data were obtained from medical records and assessed using two validated instruments: the Short Form-36 (SF-36) and the Hospital Anxiety and Depression Scale (HADS). Results: The mean age of the cohort was 39.8 ± 7.8 years, with a mean disease duration of 4.80 ± 5.37 years and a mean ASDAS of 2.09 ± 1.14. DRVs, correlated positively with HADS scores and negatively with SF-36 scores. Patients with family histories of SpA had significantly lower mental-component SF-36 scores and higher HADS-D scores. Lower quality of life was associated with DRVs, particularly disease duration. Significant associations with depressive symptoms were observed for both SpA features and DRVs. Conclusions: In women with nr-axSpA, both SpA-fs and DRVs are associated with reduced QoL and elevate the risk of anxiety and depression, underscoring the need for thorough patient evaluation that encompasses psychological health. Full article

Background/Objectives: Following lumbar fusion procedures, adjacent segment degeneration (ASD) at cranial levels presents as a well-documented long-term complication, manifesting through recurrent pain, neurological deficits, and progressive functional decline. The prone single-position technique for lateral lumbar interbody fusion (PSP-LLIF) streamlines surgical workflow by eliminating the need for intraoperative patient repositioning; however, comprehensive evidence supporting its clinical and radiological effectiveness in managing cranial ASD remains insufficient. Material and Methods: This retrospective cohort study examined 30 consecutive patients presenting with symptomatic cranial adjacent segment disease who were treated with PSP-LLIF at a single institution. Patient-reported outcome measures included visual analog scale (VAS) assessments for axial and radicular pain, alongside the Oswestry Disability Index (ODI) for functional status evaluation. Radiological parameters included overall and segmental lumbar lordotic measurements, anterior and posterior disk height, fusion status, and instrumentation-related complications. Results: At 12-month postoperative evaluation, substantial clinical improvements were demonstrated. Mean VAS reductions measured 4.7 points for axial pain and 6.5 points for radicular pain, while ODI decreased by 28.5 points (p < 0.05). Radiological assessment demonstrated mean increases of 6.3° in lumbar lordosis and 5.1° in segmental lordosis, along with significant gains in both anterior and posterior disk height (p < 0.05). Solid fusion was radiographically confirmed at all instrumented levels. Temporary postoperative neurological symptoms developed in several patients but resolved spontaneously without requiring revision surgery. Conclusions: PSP-LLIF yields substantial clinical benefit and reliable radiological correction in patients with symptomatic cranial ASD. Optimal outcomes necessitate rigorous adherence to position-specific technical modifications, particularly maintenance of perpendicular fluoroscopic trajectories and implementation of continuous neural monitoring to account for prone-induced anatomical shifts. This approach represents a viable treatment strategy for patients with symptomatic cranial ASD. Full article

Background/Objectives: Nutritional supplementation has been proposed as a potential adjunct strategy in myopia prevention and control through antioxidative, anti-inflammatory, and extracellular matrix-regulating mechanisms. This systematic review aimed to evaluate randomized controlled trial (RCT) evidence on the effects of carotenoids, anthocyanins, polyunsaturated fatty acids, and combined nutraceutical formulations on refractive outcomes, axial length, macular pigment optical density (MPOD), visual function, and symptoms of visual fatigue. Methods: The review was registered in PROSPERO (CRD420251149727) and conducted in accordance with PRISMA 2020 and AMSTAR-2 guidelines. PubMed, Web of Science, and Scopus were searched up to 5 August 2025. Eligible studies were RCTs involving individuals with myopia or at risk of myopia, comparing nutritional supplementation with placebo or active controls. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Cochrane RoB 2 tool. Results: Nine RCTs were included. Carotenoids such as crocetin, lutein, zeaxanthin, and astaxanthin produced modest benefits, including improved MPOD, reduced visual fatigue, and—in one pediatric trial—slightly less axial elongation. Anthocyanin-rich extracts improved mesopic contrast sensitivity and subjective asthenopia. A combined carotenoid–polyphenol formulation enhanced accommodative facility. However, no consistent clinically meaningful reduction in myopia progression was observed. Trials were generally small, heterogeneous, and short in duration. Conclusions: Nutritional supplementation may improve visual function and retinal antioxidant status but lacks strong evidence for slowing myopia progression. Larger, long-term RCTs are needed before recommending supplementation for routine myopia management. Full article

Background/Objectives: Deep brain stimulation (DBS) of the globus pallidus interna (GPi) is a safe and established therapy for management of refractory motor fluctuations and dyskinesia in Parkinson’s disease (PD). However, the relationship between stimulation site connectivity and improvement of axial gait symptoms remains poorly understood, particularly when stimulating in the GPi. This study investigated functional and structural connectivity patterns specifically associated with axial symptom outcomes following bilateral GPi-DBS, and, as a secondary exploratory analysis, examined whether Volumes of tissue activated (VTAs)-based connectivity related to overall UPDRS-III change. Methods: We retrospectively analyzed 19 PD patients who underwent bilateral GPi-DBS at the University of Florida (2002–2017). Unified Parkinson’s Disease Rating Scale (UPDRS-III) axial gait subscores were assessed at baseline and 36-month follow-up. VTAs were reconstructed using Lead-DBS and coregistered to Montreal Neurological Institute (MNI) space. Structural connectivity was evaluated with diffusion tractography, and functional connectivity was estimated using normative resting-state fMRI datasets. Correlations between VTA connectivity and clinical improvement were examined using Spearman correlation and voxelwise analyses. Results: Patients with axial improvement in motor scales demonstrated specific VTA connectivity to sensorimotor and supplementary motor networks, particularly lobule V and lobules I–IV of the cerebellum. These associations were specific to axial gait subscores. In contrast, worsening axial gait symptoms correlated with connectivity to cerebellar Crus II, cerebellum VIII, calcarine cortex, and thalamus (p < 0.05). Total UPDRS-III scores did not show a significant positive correlation with supplementary motor area or primary motor cortex connectivity; a non-significant trend was observed for VTA–M1 connectivity (R = 0.41, p = 0.078). Worsening total motor scores were associated with cerebellar Crus II and frontal–parietal networks. These findings suggest that distinct connectivity patterns underlie differential trajectories in axial and global motor outcomes following GPi-DBS. Conclusions: Distinct connectivity profiles might underlie axial gait symptom outcomes following GPi-DBS. Connectivity to motor and sensorimotor pathways supports improvement, whereas involvement of Crus II and occipital networks predicts worsening. Additional studies to confirm and expand on these findings are needed, but our results highlight the value of connectomic mapping for refining patient-specific targeting and developing future programming strategies. Full article